NCT06023862
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06023862
Title A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (DOVE)
Acronym DOVE
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Yonsei University
Indications
Therapies
Age Groups: senior | adult
Covered Countries GBR | AUS


No variant requirements are available.